| 查看: 1385 | 回复: 17 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
开发一种新药的惊人花费（The truly staggering cost of inventing new drugs）
|
|||
|
原文链接：http://bioluminor.biomart.cn/news/2770272.htm During the Super Bowl, a representative of the pharmaceutical company Eli Lilly posted the on the company’s corporate blog that the average cost of bringing a new drug to market is $1.3 billion, a price that would buy 371 Super Bowl ads, 16 million official NFL footballs, two pro football stadiums, pay of almost all NFL football players, and every seat in every NFL stadium for six weeks in a row. This is, of course, ludicrous. The average drug developed by a major pharmaceutical company costs at least $4 billion, and it can be as much as $11 billion. The drug industry has been tossing around the $1 billion number for years. It is based largely on a study (supported by drug companies) by Joseph DiMasi of Tufts University. It’s a nice number for the pharmaceutical industry, because it seems to justify the idea that medicines should be pricey (and increasingly, they can be very pricey, costing tens of thousands of dollars per patient per year) without making it seem that inventing new medicines is so expensive an endeavor as to be ultimately futile. But as Bernard Munos of the InnoThink Center for Research In Biomedical Innovation has noted, just adjusting that estimate for current failure rates results in an estimate of $4 billion in research dollars spent for every drug that is approved. But Munos showed me another figure, where he divided each drug company’s R&D budget by the average number of drugs approved. This was far more dramatic. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. Wanting to make this even more rigorous, Forbes (that would be Scott DeCarlo and me) took Munos’ count of drug approvals for the major pharmas and combined it with their research and development spending as reported in annual earnings filings going back fifteen years, pulled from a Thomson Reuters database using FactSet. We adjusted all the figures for inflation. Using both drug approvals and research budgets since 1997 keeps the estimates being skewed by short-term periods when R&D budgets or drug approvals changed dramatically. The range of money spent is stunning. AstraZeneca has spent $12 billion in research money for every new drug approved, as much as the top-selling medicine ever generated in annual sales; Amgen spent just $3.7 billion. At $12 billion per drug, inventing medicines is a pretty unsustainable business. At $3.7 billion, you might just be able to make money (a new medicine can probably keep generating revenue for ten years; invent one a year at that rate and you’ll do well). There are lots of expenses here. A single clinical trial can cost $100 million at the high end, and the combined cost of manufacturing and clinical testing for some drugs has added up to $1 billion. But the main expense is failure. AstraZeneca does badly by this measure because it has had so few new drugs hit the market. Eli Lilly spent roughly the same amount on R&D, but got twice as many new medicines approved over that 15 year period, and so spent just $4.5 billion per drug. |
回复此楼» 猜你喜欢
TCE药物治疗肿瘤病人后免疫细胞重建的检测
已经有18人回复
-
是不是现在考博都是推荐制？或者是已经内定了？还有通过考试招博士的学校吗？
已经有39人回复
-
药物学论文润色/翻译怎么收费?
已经有107人回复
-
农产品中农药监测的免疫传感器的疑问
已经有0人回复
-
纳米传感器监测农药残留的疑惑
已经有0人回复
-
谁有人卫版 《毒理学基础》第七版书籍
已经有0人回复
-
26有没有老师想收做定量药理的学生啊
已经有3人回复
-
26考博申请 学or专
已经有15人回复
» 抢金币啦！回帖就可以得到:
-
中飞院航空锂电池团队接受硕士生调剂
+1/74
-
国自然面上祈福
+1/71
-
艾里卡特 (Alicat) - 燃料电池测试系统与质量流量和压力仪表
+3/49
-
安徽工程大学化学与环境工程学院对外招收2026级调剂硕士研究生
+1/36
-
【分享】招收08工学硕士（要求过国家线）
+1/34
-
济南大学水利与环境学院赵艳侠教授简介
+1/23
-
南京林业大学-国家级青年人才团队 招2026级博士、调剂硕士（合成化学方向）
+1/18
-
南京林业大学木质纤维素功能材料国际联合创新中心招收2026级硕士生（调剂）
+2/18
-
西华大学材料学院表面科学与工程技术科研团队2026年招收研究生
+1/16
-
西北工业大学机电学院 复合材料加工制造方向招聘博士后
+1/15
-
【博士招生】南京林业大学车辆工程课题组招收26年9月入学“申请-考核制”博士研究生
+1/13
-
武汉工程大学资源生物技术课题组生物/环境/化工/矿冶专业硕士、博士研究生招生及调剂
+1/9
-
博士招生 | 青岛科技大学（高分子、化学、材料、力学、机电工程、计算机仿真）
+1/9
-
天津理工大学国家杰青王铁团队招聘学术骨干、博士后
+1/9
-
【博士招生】广东工业大学国家优青课题组招收2026年环境方向博士生
+1/7
-
江西科技师范大学 材料与能源招收调剂研究生
+1/7
-
南开大学环境科学与工程学院王鑫教授课题组招收申请考核制博士生
+1/6
-
机械求调剂 读研还想学机械
+1/5
-
上海师范大学有机化学专业研究生招生
+1/2
-
香港中文大学 生物医学学院/组织工程与再生医学研究所 招聘博士后/研究助理
+1/2
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
本帖内容被屏蔽 |
14楼2015-09-17 14:21:15
7楼2015-08-31 16:02:44
9楼2015-09-01 08:14:29
10楼2015-09-01 08:19:15
